References
1. Schnabel RB, Yin X, Gona P, Larson MG, Beiser A, Mcmanus DD, Newtoncheh C, Lubitz SA, Magnani JW, Ellinor PT, Seshadri S, Wolf PA, Vasan RS, Benjamin EJ, Levy D: 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015;386:154-162.
2. Zoniberisso M, Lercari F, Carazza T, Domenicucci S: Epidemiology of Atrial Fibrillation: European Perspective. Clin Epidemio 2014;6:213-220.
3. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA: Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. Clin Epidemio 2016;354:i4482
4. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, Mcanulty JH, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ: Worldwide Epidemiology of Atrial Fibrillation A Global Burden of Disease 2010 Study. Circulation 2014;129:837-847.
5. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of Diagnosed Atrial Fibrillation in Adults: National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.
6. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BHC, Stijnen T, Lip GY, Witteman JC: Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-953.
7. Thongprayoon C, Chokesuwattanaskul R, Bathini T, Khoury NJ, Sharma K, Ungprasert P, Prasitlumkum N, Aeddula NR, Watthanasuntorn K, Salim SA, Kaewput W, Koller FL, Cheungpasitporn W: Epidemiology and Prognostic Importance of Atrial Fibrillation in Kidney Transplant Recipients: A Meta-Analysis. J Clin Med 2018;7:370.
8. Chokesuwattanaskul R, Thongprayoon C, Bathini T, Ungprasert P, Sharma K, Wijarnpreecha K, Pachariyanon P, Cheungpasitporn W: Liver transplantation and atrial fibrillation: A meta-analysis. World Journal of Hepatology 2018;10:761-771.
9. Brennan DC: Long-term trends in allograft survival. Adv Chronic Kidney D 2006;13:11-17.
10. Sanchez CA, Higueras MM, Fernandez-Felechosa JM, Gutierrez JM, Moreno PM, Fernandez NG, Royo FL, Goenaga PE: Short-term outcomes of 100 consecutive kidney transplantations in a 3-year period: a single-center experience. Transpl P 2016;48:2906-2909.
11. Molinari M, Sood P, Samra PB, Tevar AD, Ganoza A, Jonassaint N, Puttarajappa C: Atrial fibrillation in renal or liver transplant recipients: A systematic review and meta-analysis. Transplantation Reviews 2019;33:29-38.
12. Bargehr J, Trejogutierrez JF, Patel TC, Rosser BG, Arandamichel J, Yataco M, Taner CB: Preexisting atrial fibrillation and cardiac complications after liver transplantation. Liver Transplant 2015;21:314-320.
13. Lenihan CR, Montezrath ME, Scandling JD, Turakhia MP, Winkelmayer WC: Outcomes After Kidney Transplantation of Patients Previously Diagnosed With Atrial Fibrillation. Am J Transplant 2013;13:1566-1575.
14. Marincasino M, Perezsaez MJ, Crespo M, Echeverria D, Mir M, Pascual J: Significant tacrolimus and dronedarone interaction in a kidney transplant recipient. Transplantation 2014;98:33-34
15. Tichy EM, Medwid AJ, Mills EA, Formica RN, Kulkarni S: Significant Sirolimus and Dronedarone Interaction in a Kidney Transplant Recipient. Ann Pharmacother 2010;44:1338-1341.
16. Burger CI, Clase CM, Gangji AS: Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. Transplantation 2010;89:1166-1167.
17. Kisters K, Cziborra M, Funke C, Brylak S, Hausberg M: Amiodarone-tacrolimus interaction in kidney transplantation. Clin Nephrol 2008;70:563.
18. Leon J, Sabbah L, Aubert O, Anglicheau D, Delavenne X, Zuber J, Amrouche L, Scemla A, Giura G, Divard G, Legendre C, Sberro-Soussan R: Efficacy and safety of direct oral anticoagulants in kidney transplantation: a single-center pilot experience. Transplantation 2020.
19. Salerno DM, Tsapepas D, Papachristos A, Chang J, Martin ST, Hardy MA, Mckeen J: Direct oral anticoagulant considerations in solid organ transplantation: A review. Clin Transplant 2017;31: 10.1111/ctr.12873
20. Calkins H, Hindricks G, Cappato R, et al: 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2017;14:275-444.
21. Dong JZ, Sang CH, Yu RH, Long DY, Tang RB, Jiang CX, Ning M, Liu N, Liu XP, Du X, Tse HF, Ma CS: Prospective randomized comparison between a fixed ‘2C3L’ approach vs. stepwise approach for catheter ablation of persistent atrial fibrillation. Europace 2015;17:1798-1806.
22. De Mattos AM, Prather JC, Olyaei AJ, Shibagaki Y, Keith D, Mori M, Norman DJ, Becker T: Cardiovascular events following renal transplantation: Role of traditional and transplant-specific risk factors. Kidney Int 2006;70:757-764.
23. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J: Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002;73:901-906.
24. Fussner LA, Heimbach JK, Fan C, Dierkhising RA, Coss E, Leise MD, Watt KD: Cardiovascular disease after liver transplantation: When, What, and Who Is at Risk. Liver Transplant 2015;21:889-896.
25. Rabkin JM, Corless CL, Rosen HR, Olyaei AJ: Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 2002;183:595-599.
26. Gill JS: Cardiovascular Disease in Transplant Recipients: Current and Future Treatment Strategies. Clin J Am Soc Nephrol 2008;3:S29-37
27. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch K, Monahan KH, Daniels MR, Bahnson TD, Poole JE, Rosenberg Y, Lee KL, Packer DL; CABANA Investigators: Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA 2019;321:1275-1285.
28. Blomstromlundqvist C, Gizurarson S, Schwieler J, Jensen SM, Bergfeldt L, Kenneback G, Rubulis A, Malmborg H, Raatikainen P, Lonnerholm S, Hoglund N, Mortsell D: Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation: The CAPTAF Randomized Clinical Trial. JAMA 2019;321:1059-1068.
29. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma LVA, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, Bansch D; CASTLE-AF Investigators: Catheter Ablation for Atrial Fibrillation with Heart Failure. New Engl J Med 2018;378:417-427.
30. Lin H, Wolf PA, Kellyhayes M, Beiser A, Kase CS, Benjamin EJ, D’Agostino RB: Stroke Severity in Atrial Fibrillation The Framingham Study. Stroke 1996;27:1760-1764.
31. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbuchel H; ESC Scientific Document Group: The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330-1393.
32. Lenihan CR, Montezrath ME, Shen JI, Scandling JD, Turakhia MP, Chang TI, Winkelmayer WC: Correlates and outcomes of warfarin initiation in kidney transplant recipients newly diagnosed with atrial fibrillation. Nephrol Dial Transpl 2015;30:321-329.
33. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-962.
34. Vanhove T, Spriet I, Annaert P, Maertens J, Van Cleemput J, Vos R, Kuypers D: Effect of the Direct Oral Anticoagulants Rivaroxaban and Apixaban on the Disposition of Calcineurin Inhibitors in Transplant Recipients. Ther Drug Monit 2017;39:77-82.
35. Wannhoff A, Weiss KH, Schemmer P, Stremmel W, Gotthardt D: Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. Transplantation 2014;98:12-13